
A randomized, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension

Czepiel, KS. et al. *Thorax* 2025. DOI: 10.1136/thorax-2024-222725



Pre-clinical & Phase I Trial: 4-MU decreases lung tissue HA by inhibiting its synthesis

Participants: 16 adult patients with either PAH or PH-ILD.

Hymecromone N=10

R ~5:3

Placebo N=6

Duration: 24 weeks

Phase IIa Randomized Clinical Trial: 4-MU is safe in patients with PAH and PH-ILD

PVR did not significantly improve

6MWD improved in PH-ILD*

HRQOL improved in PH-ILD*

Functional Outcomes: 4-MU improves secondary endpoints in PH-ILD*

*Findings are clinically meaningful but not statistically significant.